Revenue showed a marginal decline at Rs. 0.00 millions. For the quarter ended September 2018, as compared to corresponding quarter of last year.The company almost doubled its revenue to Rs. 2.75 millions  from Rs. 1.22 millions in the quarter ended September 2018.Operating Profit saw a handsome growth to 2.75 millions from 1.22 millions in the quarter ended September 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201809 201709 % Var 201809 201709 % Var 201703 201603 % Var Sales 0.00 1.90 0.00 1.90 36.70 -94.82 34.80 456.70 -92.38 Other Income 2.79 2.16 29.17 4.95 13.03 -62.01 10.86 12.18 -10.84 PBIDT 2.75 1.22 125.41 3.97 1.30 205.38 0.08 0.83 -90.36 Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PBDT 2.75 1.22 125.41 3.97 1.30 205.38 0.08 0.83 -90.36 Depreciation 0.00 0.00 0.00 0.00 0.04 0.00 0.04 0.07 -42.86 PBT 2.75 1.22 125.41 3.97 1.26 215.08 0.04 0.76 -94.74 TAX 0.00 0.00 0.00 0.00 -0.01 0.00 -0.01 0.24 -104.17 Deferred Tax 0.00 0.00 0.00 0.00 -0.02 0.00 -0.02 0.00 0.00 PAT 2.75 1.22 125.41 3.97 1.28 210.16 0.05 0.52 -90.38 Equity 36.24 36.24 0.00 36.24 36.24 0.00 36.24 36.24 0.00 PBIDTM(%) 0.00 64.21 -100.00 208.95 3.54 5798.80 0.23 0.18 26.53

Lifeline Drugs & Pharma has informed that a meeting of the Board of Directors of the Company will be held on May 03, 2016, to Shift Registered Office of the Company, and to consider appointment of new Director/s and to accept resignation of existing Director/s.The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed about Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed about Standalone Financial Results and Standalone Limited Review for the period ended December 31, 2015.The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed about Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has submitted a copy of the limited review report for the period ended September 30, 2015The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed about the Standalone Financial Results for the period ended September 30, 2015.The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed that the Board of Directors of the Company at its meeting held on May 27, 2014, have accepted the resignation of Anil Sanklecha from the Board of Directors w.e.f. May 27, 2014.The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed that the company has fixed June 20, 2014 as the Record Date for the purpose of payment of Interim Dividend. The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed that the Board of Directors of the company at its meeting held on June 06, 2014, has approved payments of Interim Dividend @ 0.10 paise on Equity Share of Rs 1 each for financial year 2014-15. The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed that a meeting of the Board of Directors of the Company will be held on June 03, 2014, to consider payment of Dividend. The above information is a part of company’s filings submitted to BSE.

Lifeline Drugs & Pharma has informed that an Extra Ordinary General Meeting (EGM) of the company will be held on October 28, 2013.The above information is a part of company’s filings submitted to BSE.